In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire makes $30bn hostile offer for Baxalta; finalized at $32bn

Executive Summary

Shire PLC took an unsolicited offer to acquire newly public Baxalta Inc. directly to Baxalta's board: Shire would issue 0.1687 ADRs for each Baxalta share, valuing the deal at $30bn or approximately $44.06 per share (a 39% premium). Upon closing, Baxalta would own 37% of the combined company, but within two years Shire plans to repurchase up to 13% of the combined shares via a share buyback.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies